Drug Patents owned by Foldrx Pharms

1. Drug name - VYNDAMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Apr, 2024

(1 year, 6 months from now)

US9770441 FOLDRX PHARMS Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Aug, 2035

(12 years from now)

CN100448852C FOLDRX PHARMS Stable Thyroxine Carrier Protein And Compositions And Methods For Inhibiting Transthyretin Misfolding Lipocalin.
Dec, 2023

(1 year, 2 months from now)

CN1747965A FOLDRX PHARMS Stabilizing Transthyretin And Inhibiting Transthyretin Protein Misfolding Of Composition And Method
Dec, 2023

(1 year, 2 months from now)

CN101413143A FOLDRX PHARMS Compositions And Methods For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

CN101413143B FOLDRX PHARMS Stable Thyroxine Carrier Protein And Compositions And Methods For Inhibiting Transthyretin Misfolding Lipocalin.
Dec, 2023

(1 year, 2 months from now)

IN200501588P4 FOLDRX PHARMS Composition And Methods For Stablizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

IN230323B FOLDRX PHARMS A Compound For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP2325651A3 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1988397B8 FOLDRX PHARMS Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1988397A1 FOLDRX PHARMS Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1988397B1 FOLDRX PHARMS Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP2325651B1 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP2325651A2 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1587821A4 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Nov, 2026

(4 years from now)

EP1587821A2 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Nov, 2026

(4 years from now)

EP1587821B1 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Nov, 2026

(4 years from now)

EP3191461A1 FOLDRX PHARMS Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Aug, 2035

(12 years from now)

EP3191461B1 FOLDRX PHARMS Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using TAFAMIDIS ingredient

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
61MG CAPSULE;ORAL Prescription

2. Drug name - VYNDAQEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168663 FOLDRX PHARMS Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
Dec, 2023

(1 year, 2 months from now)

US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Apr, 2024

(1 year, 6 months from now)

CN100448852C FOLDRX PHARMS Stable Thyroxine Carrier Protein And Compositions And Methods For Inhibiting Transthyretin Misfolding Lipocalin.
Dec, 2023

(1 year, 2 months from now)

CN1747965A FOLDRX PHARMS Stabilizing Transthyretin And Inhibiting Transthyretin Protein Misfolding Of Composition And Method
Dec, 2023

(1 year, 2 months from now)

CN101413143A FOLDRX PHARMS Compositions And Methods For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

CN101413143B FOLDRX PHARMS Stable Thyroxine Carrier Protein And Compositions And Methods For Inhibiting Transthyretin Misfolding Lipocalin.
Dec, 2023

(1 year, 2 months from now)

IN200501588P4 FOLDRX PHARMS Composition And Methods For Stablizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

IN230323B FOLDRX PHARMS A Compound For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP2325651A3 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1988397B8 FOLDRX PHARMS Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1988397A1 FOLDRX PHARMS Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1988397B1 FOLDRX PHARMS Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP2325651B1 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP2325651A2 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Dec, 2023

(1 year, 2 months from now)

EP1587821A4 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Nov, 2026

(4 years from now)

EP1587821A2 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Nov, 2026

(4 years from now)

EP1587821B1 FOLDRX PHARMS Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
Nov, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec, 2023

(1 year, 2 months from now)

US8653119 FOLDRX PHARMS Methods for treating transthyretin amyloid diseases Jan, 2024

(1 year, 3 months from now)

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.